Furthermore, several anti-tumor agents were shown to induce IL-1β mostly in a NLRP3 inflammasome–dependent manner [60]; therefore, the treatment of tumors with the combination of conventional agents and anti-IL-1β has been adapted. Here, IL1B is linked to neoplasm.